GnRH agonist treatment regulates IL-6 and IL-11 expression in endometrial stromal cells for patients with HRT regiment in frozen embryo transfer cycles

Li, Lifei; Liu, Lin; Kou, Zhijian; Huo, Ming; An, Jun‐Xia; Zhang, Xuehong

doi:10.1016/j.repbio.2022.100608

Cited by 9 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, relevant studies implied that the expression of the endometrial receptivity markers, such as LIF and integrin αvβ3, significantly increased in groups with the GnRHa pretreatment compared with the group without GnRHa. [21] This study further revealed that GnRHa improved the endometrial receptivity via elevation of IL-6 and IL-11 in the endometrium. Meanwhile, in vitro experiments of endometrial stromal cells suggested that GnRHa regulated Il-6 and IL-11 through miR-124.…”

Section: Discussionmentioning

confidence: 68%

“…[21] However, several previous studies showed conflicting results. Certain investigations reported similar pregnancy outcomes, [22][23][24][25] while some indicated the superiority of HRT-FET with GnRHa [21,26] or without GnRHa. [27] But for certain infertility patients, GnRHa may be more beneficial.…”

Section: Discussionmentioning

confidence: 99%

“…The latest report also showed clinical pregnant rate was increased from 37.68 to 46.1% among patients with various disease context under the GnRHa pretreatment. [21] However, several previous studies showed conflicting results. Certain investigations reported similar pregnancy outcomes, [22][23][24][25] while some indicated the superiority of HRT-FET with GnRHa [21,26] or without GnRHa.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

STROBE-GnRHa pretreatment in frozen-embryo transfer cycles improves clinical outcomes for patients with persistent thin endometrium: A case-control study

Liu

Zhu

et al. 2022

Medicine

View full text Add to dashboard Cite

The well-prepared endometrium with appropriate thickness plays a critical role in successful embryo implantation. The thin endometrium is the main factor of frozen-embryo transfer (FET), resulting in the failure of implantation undergoing FET. Hormone treatment is suggested to improve endometrium thickness; however, among the larger numbers of cases, it cannot reach the sufficient thickness, which leads to a high cancelation rate of embryo transfer as well as waste high-quality embryos. Thus, it increases the burden to patients in both economic and psychological perspectives. We performed a retrospective observational study, which was composed with 2 cohorts, either with the conventional hormone replacement therapy (HRT) protocol or HRT with gonadotrophin-releasing hormone agonist (GnRHa) pretreatment to prepare the endometrium before FET. The measurements of endometrium thickness, hormone level, transfer cycle cancelation rate, pregnancy rate, and implantation rate were retrieved from the medical records during the routine clinic visits until 1 month after embryo transfer. The comparisons between 2 cohorts were performed by t-test or Mann-Whitney U test depending on the different attributions of data. In total, 49 cycles were under HRT with GnRHa pretreatment and 84 cycles were under the conventional HRT protocol. HRT with GnRHa pretreatment group improved the endometrial thickness (8.13 ± 1.79 vs 7.51 ± 1.45, P = .031), decreased the transfer cancelation rate (P = .003), and increased clinical pregnancy rate and implantation rate significantly (both P = .001). Additionally, luteinizing hormone level in pretreatment group was consistently lower than conventional HRT group (P < .05). Our study revealed HRT with GnRHa pretreatment efficiently improved the endometrial thickness, therefore, decreased the FET cycle cancelation. It also elevated the embryo implantation rate and clinical pregnancy rate by improving endometrial receptivity.Abbreviations: AdjOR = adjusted odds ratio, BMI = body mass index, E2 = estradiol, Em = increased endometrial thickness, FET = frozen-embryo transfer, FSH = follicle stimulating hormone, GnRHa = gonadotrophin-releasing hormone agonist, hCG = human chorionic gonadotrophin, HRT = hormone replacement therapy, LH = luteinizing hormone, ROC = receiver operating characteristic, SD = standard deviation.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

STROBE-GnRHa pretreatment in frozen-embryo transfer cycles improves clinical outcomes for patients with persistent thin endometrium: A case-control study

Liu

Zhu

et al. 2022

Medicine

View full text Add to dashboard Cite

show abstract

“…Both GnRH and GnRH-R have been reported to be expressed in both the epithelium and the stroma of the endometrium and reach the highest levels in the secretory phase of the menstrual cycle (7,8,29,30), suggesting that the GnRH-GnRH-R pathway has functional roles in endometrium receptivity and implantation. GnRHa therapy may enhance the expression of endometrial integrin αvβ3, an adhesive molecule, and implantation-related factors, such as HOXA10 and LIF, in humans (11,12) and mice (31,32). Furthermore, in a study of human decidual stromal cells, GnRH has been found to be able to modulate matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue-speci c inhibitor of matrix metalloproteinases (TIMPs) (33), both of which are associated with cyclic remodeling of the endometrium and decidualization (34).…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, GnRH agonists (GnRHa) may have direct effects and functional roles in the endometrium and embryos. Indeed, GnRH has been reported to enhance endometrium receptivity and embryo development (11)(12)(13)(14).Several systematic reviews and metaanalyses indicated that adding GnRHa to progesterone signi cantly improved the ongoing pregnancy rate and live birth rate compared with using progesterone alone for luteal phase support in fresh embryo transfer (fET) cycles (15)(16)(17)(18). Furthermore, a systematic review and meta-analysis including 20 studies and 5497 patients demonstrated that GnRHa administration in the luteal phase boosted the clinical pregnancy rate in both fET and FET cycles, and the bene cial effect was similar between the fET and FET cycles (19).…”

Section: Introductionmentioning

confidence: 99%

Additional single dose GnRH agonist during luteal phase support may improve live birth rate in GnRHa-HRT frozen–thawed embryo transfer cycle: a retrospective cohort study

Chang

Lin

et al. 2023

Preprint

View full text Add to dashboard Cite

Background GnRH agonist (GnRHa) has been reported to have direct effects and functional roles in the endometrium and embryos. Several meta-analyses have shown that GnRHa administration in the luteal phase improved the live birth rate or pregnancy rate in both fresh and frozen embryo transfer (FET) cycles. The aim of this study was to investigate whether luteal GnRHa administration could also improve in vitro fertilization (IVF) outcomes in patients undergoing hormone replacement therapy (HRT) cycles with GnRHa suppression. Methods The retrospective cohort study included a total of 414 patients undergoing GnRHa-HRT FET cycles. The study group included 216 patients receiving an additional single dose of GnRHa in the luteal phase following embryo transfer. A total of 198 patients in the control group did not receive luteal GnRHa. The baseline and cycle characteristics and reproductive outcomes were compared between the two groups. Results Baseline and cycle characteristics were similar between the two groups, except lower AMH levels were found in the luteal GnRHa group than in the control group. The luteal GnRHa group had a significantly higher ongoing pregnancy rate and live birth rate than the control group. The multivariate analysis revealed that luteal GnRHa administration was positively associated with ongoing pregnancy (OR 1.66, 95% CI 1.01–2.72, P = 0.048) and live birth (OR 1.67, 95% CI 1.01–2.75, P = 0.044). When the subgroup of patients with recurrent implantation failure (RIF) was analyzed, the multivariate analysis also showed that luteal GnRHa administration had beneficial effects on ongoing pregnancy (OR 2.79, 95% CI 1.14–6.82, P = 0.024) and live birth (OR 2.89, 95% CI 1.15–7.22, P = 0.023). Conclusions Our data suggest that the addition of one luteal dose of GnRHa may improve the live birth rate in patients undergoing the GnRHa-HRT protocol, especially in RIF patients.

show abstract

Hormone replacement therapy with GnRH agonist pretreatment improves pregnancy outcomes in patients with previous intrauterine adhesions

Zheng

Zhang

et al. 2022

Journal of Gynecology Obstetrics and Human Reproduction

View full text Add to dashboard Cite

GnRH agonist treatment regulates IL-6 and IL-11 expression in endometrial stromal cells for patients with HRT regiment in frozen embryo transfer cycles

Cited by 9 publications

References 23 publications

STROBE-GnRHa pretreatment in frozen-embryo transfer cycles improves clinical outcomes for patients with persistent thin endometrium: A case-control study

STROBE-GnRHa pretreatment in frozen-embryo transfer cycles improves clinical outcomes for patients with persistent thin endometrium: A case-control study

Additional single dose GnRH agonist during luteal phase support may improve live birth rate in GnRHa-HRT frozen–thawed embryo transfer cycle: a retrospective cohort study

Hormone replacement therapy with GnRH agonist pretreatment improves pregnancy outcomes in patients with previous intrauterine adhesions

Contact Info

Product

Resources

About